Skip to main content
Premium Trial:

Request an Annual Quote

Pacific Edge, PPO MultiPlan Sign Deal Covering Bladder Cancer Dx

NEW YORK (GenomeWeb) – Pacific Edge recently announced a contract with preferred provider organization MultiPlan covering Pacific Edge's Cxbladder test.

The deal provides coverage of the bladder cancer test to MultiPlan's members and includes Pacific Edge's participation in the MultiPlan, PHCS, and PHCS Savility Networks. About 900,000 providers participate in MultiPlan's networks and about 68 million patients have access to the networks, Pacific Edge said.

The Cxbladder test is urine-based and comprises five biomarkers. It identifies patients with changes in gene expression and helps rule out cancer in patients with normal gene expression. The test is run out of the company's wholly owned subsidiary Pacific Edge Diagnostics' CAP-accredited laboratory in Hershey, Pa.

Earlier this year, Pacific Edge received NZ$4.5 million (US$3.8 million) from New Zealand crown entity Callaghan Innovation to accelerate the firm's development of molecular cancer detection technology.

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.